References of "Piette, Marie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailZelfbehandeling van frequente hoofdpijn : een Belgische apotheekstudie
Mehuys, E; Paemeleire, K; Van Hees, Thierry ULg et al

Conference (2012, September)

Detailed reference viewed: 12 (9 ULg)
Full Text
Peer Reviewed
See detailAutomédication des céphalées fréquentes : étude dans les officines belges.
Mehuys, Els; Paemeleire, Koen; Van Hees, Thierry ULg et al

in Journal de Pharmacie de Belgique (2012), 2

AIM: This observational community pharmacy-based study aimed to investigate headache characteristics and medication use of persons with regular headache presenting for self-medication. METHODS ... [more ▼]

AIM: This observational community pharmacy-based study aimed to investigate headache characteristics and medication use of persons with regular headache presenting for self-medication. METHODS: Participants (n=1205) completed ii) a questionnaire to assess current headache medication and previous physician diagnosis, (ii) the ID Migraine Screener [ID-M] and (iii) the MIDAS questionnaire. RESULTS: Forty-four % of the study population (n=528) did not have a physician diagnosis of their headache, and 225 of them (225/528, 42.6%) were found to be ID-M positive. The most commonly used acute headache drugs were paracetamol (used by 62% of the study population), NSAIDs (39%) and combination analgesics (36%). Only 12% of patients physician-diagnosed with migraine used prophylactic migraine medication, and 25% used triptans. About 24% of our sample (n=292) chronically overused acute medication, which was combination analgesic overuse (n=166), simple analgesic overuse (n=130), triptan overuse (n=19), ergot overuse (n=6) and opioid overuse (n=51). Only 14.5% was ever advised to limit intake frequency of acute headache treatments. CONCLUSIONS: This study identified underdiagnosis of migraine, low use of migraine prophylaxis and triptans, and high prevalence of medication overuse among subjects seeking self-medication for regular headache. Community pharmacists have a strategic position in education and referral of these self-medicating headache patients. [less ▲]

Detailed reference viewed: 91 (22 ULg)
See detailFrom the Clinics to the Bench and back to the Clinics: design of a medical treatment for Cervical Intraepithelial Neoplasia (CIN)
Jost, Maud; Frankenne, Francis; Maillard, Catherine ULg et al

Conference (2011, May 20)

Detailed reference viewed: 27 (12 ULg)
Peer Reviewed
See detailPreparations and characterisations of semi-solid formulations containing a hydrophilic drug for vaginal administration
Coia, Isabelle ULg; Evrard, Brigitte ULg; Piette, Marie ULg

Poster (2009, April 01)

The purpose of this study is to demonstrate the effect of different types of semi-solid formulations (aqueous gels, liquid jellified emulsions and hydrophilic or lipophilic creams) for vaginal ... [more ▼]

The purpose of this study is to demonstrate the effect of different types of semi-solid formulations (aqueous gels, liquid jellified emulsions and hydrophilic or lipophilic creams) for vaginal administration on the release kinetic of a hydrophilic drug. This drug is an acidic and hydrophilic (log P (octanol/water) = -3.3) molecule with an aqueous solubility upper than 170mg/ml at pH 6-8. The formulations characterisations consisted in the in vitro evaluation of the drug release kinetic and the measure of all formulations viscosity as well as the creams stability and emulsions droplets size. [less ▲]

Detailed reference viewed: 17 (6 ULg)
Full Text
Peer Reviewed
See detailStudy of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes
Piel, Géraldine ULg; Piette, Marie ULg; Barillaro, Valery et al

in International Journal of Pharmaceutics (2007), 338(1-2), 35-42

It is well known that cyclodextrins are able to extract lipids constituting membranes, increasing their fluidity and permeability. This behaviour towards biological membranes is directly linked to the ... [more ▼]

It is well known that cyclodextrins are able to extract lipids constituting membranes, increasing their fluidity and permeability. This behaviour towards biological membranes is directly linked to the toxicological effects of methylated cyclodextrins. However, confusion is currently made in the literature between the different methylated cyclodextrin derivatives. Moreover, a new methylated cyclodextrin derivative recently occurred in the market. the Crysmeb (R). We wanted to compare and understand the effect of the most currently used cyclodextrins on a model membrane. We studied the influence of natural cyclodextrins (beta CD and gamma CD), methylated derivatives (2,6-dimethyl-beta CD (Dimeb), 2,3,6-trimethyl-beta CD (Trimeb) and randomly methylated-beta CD (Rameb), as well as the new derivative Crysmeb), hydroxypropylated derivatives (HP beta CD of different substitution degrees and HP gamma CD) and the sulfobutylated derivative (SBE beta CD) on the release of a fluorescent marker encapsulated in the inner cavity of liposomes. It was shown that the observed effect on calcein release can be directly related to the affinity of cyclodextrins for both lipid components of liposomes, cholesterol and phosphatidylcholine. From this relationship, we were able to determine, for each cyclodextrin, a theoretical concentration giving rise to 50% or 100% calcein release. This theoretical concentration was confirmed experimentally. We have also showed that cyclodextrins which provoke calcein release also induce large structure modifications of liposomes. (c) 2007 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 38 (11 ULg)
Full Text
Peer Reviewed
See detailStudy of the interaction between cyclodextrins and liposome membranes: effect on the permeability of liposomes
Piel, Géraldine ULg; Piette, Marie ULg; Barillaro, Valery et al

in Journal of Inclusion Phenomena and Macrocyclic Chemistry (2007, April), 57(1-4), 309-311

We wanted to compare and understand the effect of the most currently used cyclodextrins on a model membrane. We studied the influence of most currently used cyclodextrins on the release of a fluorescent ... [more ▼]

We wanted to compare and understand the effect of the most currently used cyclodextrins on a model membrane. We studied the influence of most currently used cyclodextrins on the release of a fluorescent marker encapsulated in the inner cavity of SUV liposomes. It was shown that the observed effect on calcein release can be directly related to the affinity of cyclodextrins for both lipid components of liposomes, cholesterol and phosphatidylcholine. From this relationship, we were able to determine, for each cyclodextrin, a theoretical concentration giving rise to 50% or 100% calcein release. This theoretical concentration was confirmed experimentally. [less ▲]

Detailed reference viewed: 94 (7 ULg)
Full Text
Peer Reviewed
See detailPreparation and evaluation of liposomes encapsulating synthetic MMP inhibitor (Ro 28-2653) - cyclodextrin complexes
Piette, Marie ULg; Castagne, Delphine ULg; Delattre, Luc ULg et al

in Journal of Inclusion Phenomena and Macrocyclic Chemistry (2007, April), 57(1-4), 101-103

In this study, preparation and evaluation of liposomes, intended for intravenous administration, encapsulating synthetic MMP inhibitor (Ro 28-2653) - cyclodextrin complexes were realized. An increase in ... [more ▼]

In this study, preparation and evaluation of liposomes, intended for intravenous administration, encapsulating synthetic MMP inhibitor (Ro 28-2653) - cyclodextrin complexes were realized. An increase in Ro solubility, via formation of binary (Ro/HP beta CD) or ternary (Ro/HP beta CD/L-lysine) complexes, permitted a similar increase in encapsulation efficiency of liposomes (Table 1). Moreover, Ro release kinetics depend on the encapsulation efficiency. [less ▲]

Detailed reference viewed: 79 (9 ULg)
Full Text
Peer Reviewed
See detailContribution of cyclodextrins in the developement of different pharmaceutical formulations of a nex matrix metalloproteinase inhibitor
Evrard, Brigitte ULg; Bertholet, Pascal; Guéders, Maud ULg et al

in Journal of Inclusion Phenomena and Molecular Recognition in Chemistry (2007), 57(1-4), 303-308

Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors ... [more ▼]

Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors progression and is potentially effective against bronchial remodeling in asthma and BPCO. Ro 28-2653 is very poorly soluble in water. This low solubility estimated at about 0.56 lg/ml in water at 25 C gives rise to difficulties in pharmaceutical formulation of oral, injectable or <br />nebulizable solutions. The purpose of our study is to prepare and to characterize inclusion complexes between Ro 28-2653 and cyclodextrins and to investigate the biopharmaceutical repercussion of the inclusion of the active substance.The complex formation was investigated by phase solubility studies. 1H-NMR spectroscopy and molecular modeling studies were carried out to elucidate the structure of the inclusion <br />complex between Ro 28-2653 and cyclodextrin. Oral, intravenous and nebulizable solutions of Ro 28-2653 were developed with cyclodextrin. The in vivo studies were performed on healthy sheep for the pharmacokinetic evaluation of the oral and intravenous formulations while the nebulization of the complex solution was studied by using an asthma model in mouse. [less ▲]

Detailed reference viewed: 73 (22 ULg)
Full Text
Peer Reviewed
See detailPharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions
Piette, Marie ULg; Evrard, Brigitte ULg; Frankenne, Francis et al

in European Journal of Pharmaceutical Sciences (2006), 28(3), 189-195

Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) is a new synthetic inhibitor of matrix metalloproteinases (MMPs) with a high selectivity towards MMP2, MMP9 and ... [more ▼]

Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) is a new synthetic inhibitor of matrix metalloproteinases (MMPs) with a high selectivity towards MMP2, MMP9 and membrane type 1-MMP. It has been shown that cyclodextrins (CDs) are able to form inclusion complexes with Ro 28-2653 and to increase its aqueous solubility. The aim of this study is to demonstrate that an increase in Ro 28-2653 solubility, via ternary complex formation, can lead to an increase in the oral bioavailability of this drug. This study shows that a synergistic effect exists between hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and L-lysine. The use of this multicomponent system enabled the preparation of oral and intravenous solutions of Ro 28-2653. In vivo evaluation of the oral solution of the inclusion complex of Ro 28-2653 in comparison with a suspension of the same uncomplexed drug showed a significant (p < 0.05) increase in absolute bioavailability. The area under curve (AUC) and the peak serum concentration (C-max) were approximately 10 times higher than those obtained with the suspension, while the time (T-max) to reach C-max was reduced. Moreover, in vivo administration of Ro 28-2653 solutions highlighted some information about the pharmacokinetic behavior of Ro 28-2653: a long biologic half-life (about 15.5 h) and a small overall volume of distribution (81). (c) 2006 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 80 (17 ULg)
Full Text
Peer Reviewed
See detailBetamethasone-in-cyclodextrin-in-liposome: The effect of cyclodextrins on encapsulation efficiency and release kinetics
Piel, Géraldine ULg; Piette, Marie ULg; Barillaro, Valery et al

in International Journal of Pharmaceutics (2006), 312(1-2), 75-82

Lipophilic drugs have limited solubility in phospholipid systems, hence maximum entrapment levels in liposomes are known to be low. "Drugs-in-cyclodextrin-in-liposome" systems were previously proposed to ... [more ▼]

Lipophilic drugs have limited solubility in phospholipid systems, hence maximum entrapment levels in liposomes are known to be low. "Drugs-in-cyclodextrin-in-liposome" systems were previously proposed to overcome this drawback but studies were limited to beta CD and HP beta CD. In some cases, other cyclodextrins may be more interesting than beta CD or HPPCD, such as methylated cyclodextrins. However, these cyclodextrins are known to extract lipid components from the lipid membrane, which may destabilize liposomes. We tested the influence of several cyclodextrins (beta CD, gamma CD, Dimeb, Trimeb, Crysmeb, Rameb, HP beta CD and HP gamma CD) on the aqueous solubility of betamethasone by phase solubility diagrams and on the encapsulation efficiency in liposomes. The release kinetics of betamethasone was studied using Franz diffusion cells. We showed that release kinetics are directly correlated with encapsulation efficiency, which is closely related to betamethasone concentration in cyclodextrin complex solution. No liposome destruction was observed, even with the testing of methylated cyclodextrins at the highest concentration (40 mM). This can be explained by the fact that these cyclodextrins have a higher affinity for betamethasone than for cholesterol. This was proved by the comparison of phase solubility diagrams of both betamethasone and cholesterol. (c) 2006 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 68 (12 ULg)
Full Text
Peer Reviewed
See detailEtude des performances d'appareils de melange Unguator pour la preparation magistrale a usage dermatologique
Stassen, T.; Piette, Marie ULg; Kinget, R. et al

in Journal de Pharmacie de Belgique (2006), 61(1), 1-10

Detailed reference viewed: 67 (13 ULg)
Peer Reviewed
See detailEffect of cyclodextrins on the membrane permeability of liposomes
Piel, Géraldine ULg; Piette, Marie ULg; Barillaro, Valery et al

Poster (2005, November)

Detailed reference viewed: 23 (2 ULg)